Skip to Main Content

Paper Details

Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.
J Natl Cancer Inst
1
2024
CHT, PCa, PSA, SPOP, TP53, TP53 mutations, Tumor, androgen, androgen receptor, androgen receptor-regulated, cell cycle, and neuroendocrine genes, cancer, cell cycle-related gene, docetaxel, mRNA, patients, prostate cancer, tissues, tumor, tumor fraction
Author NameAffiliation
Andrea SbonerEnglander Institute for Precision Medicine
Andrea SbonerEnglander Institute for Precision Medicine
Matti AnnalaUniversity of British Columbia
Michael SigourosEnglander Institute for Precision Medicine
Ladan FazliUniversity of British Columbia
Mary-Ellen TaplinDana-Farber Cancer Institute
Michael J Morris
Martin E GleaveUniversity of British Columbia
Alexander W WyattUniversity of British Columbia
Himisha BeltranDana-Farber Cancer Institute
Himisha BeltranDana-Farber Cancer Institute
  • 1 - 11

Datasets

Release 1.2